...
首页> 外文期刊>Current drug delivery >Gastroretentive Ranitidine Hydrochloride Tablets with Combined Floating and Bioadhesive Properties: Factorial Design Analysis, In Vitro Evaluation and In Vivo Abdominal X-Ray Imaging
【24h】

Gastroretentive Ranitidine Hydrochloride Tablets with Combined Floating and Bioadhesive Properties: Factorial Design Analysis, In Vitro Evaluation and In Vivo Abdominal X-Ray Imaging

机译:具有浮动和生物粘附特性的胃滞留雷尼替丁盐酸盐片:因子设计分析,体外评估和体内腹部X射线成像

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Ranitidine HCl is an H-2-antagonist that suffers from low oral bioavailability of 50%. The site-specific absorption from the upper part of the small intestine and the colonic metabolism of the drug could partially contribute to its reduced bioavailability. To surmount these drawbacks, this work aimed at the formulation of Ranitidine HCl gastroretentive floating-biaodhesive tablets. A 3(2) factorial design was applied to assess the effects of matrix former (HPMC K100M): drug ratio, and the release retardant (Carbopol 971) amount on the characteristics of the tablets prepared using direct compression technique. The prepared tablets were thoroughly evaluated for physical properties, floating, swelling, bioadhesive and in vitro release behaviors. Statistical analysis of the results revealed significant effects for both formulation variables on the swelling index, maximum detachment force and cumulative percent drug released after 6 hours. In addition, the matrix-former: drug ratio showed a statistically significant effect on the floating lag time. Kinetic analysis of the release data indicated Higuchi diffusion kinetics and anomalous transport mechanism for all formulations. Scanning electron micrographs of the selected tablet formulation; F8, revealed intact surface without any perforations or channels in the dry state, while polymer expansion (relaxation) with some perforated areas were observed on the surface of the tablets after 12 hours dissolution in 0.1 N HCl. Furthermore, in vivo abdominal x-ray imaging showed good floating behavior of the selected formulation; F8, for up to 6 hours with appropriate bioadhesive property. In conclusion, the selected ranitidine HCl floating-bioadhesive tablets could be regarded as a promising gastroretentive drug delivery system that could deliver the drug at a controlled rate.
机译:盐酸雷尼替丁是一种H-2-拮抗剂,口服生物利用度低,仅为50%。小肠上部部位的位点特异性吸收和药物的结肠代谢可能部分导致其生物利用度降低。为了克服这些缺点,这项工作旨在制备盐酸雷尼替丁胃滞留性浮动抗粘连片剂。应用3(2)因子设计来评估基质形成剂(HPMC K100M):药物比例和释放延迟剂(Carbopol 971)量对使用直接压片技术制备的片剂的影响。对制备的片剂进行了物理性能,漂浮,溶胀,生物粘附和体外释放行为的彻底评估。结果的统计分析显示,两种制剂变量均对溶胀指数,最大脱离力和6小时后释放的累积百分数有显着影响。另外,基质-前体:药物比例对漂浮滞后时间显示出统计学上显着的影响。释放数据的动力学分析表明所有制剂均具有Higuchi扩散动力学和异常转运机制。所选片剂的扫描电子显微镜照片; F8在干燥状态下显示完整的表面,没有任何穿孔或通道,而在0.1 N HCl中溶解12小时后,在片剂表面观察到聚合物膨胀(松弛)并带有一些穿孔区域。此外,体内腹部X射线成像显示所选配方具有良好的漂浮性能。 F8,长达6小时,并具有适当的生物粘附特性。总之,所选的雷尼替丁HCl漂浮生物粘附片可以被视为有前途的胃滞留药物递送系统,可以以受控的速率递送药物。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号